The company said, “As announced in February 2024, the U.S. Food and Drug Administration issued a Complete Response Letter to our New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia. Interactions with the FDA continue with the goal of addressing questions raised in the CRL.” Cash Position: Cash, cash equivalents and restricted cash at September 30, 2024 were approximately $26.6 million, as compared to $41.0 million at December 31, 2023.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NERV: